

# Colon Case Study

onco*type* DX<sup>®</sup>  
*Colon Cancer Assay*

## 52-Year-Old Female Patient

**Tumor Type:** Adenocarcinoma

**Tumor Stage:** Stage III A/B (N1-3)

**Histologic Grade:** Low (1)

**Lymph Node Status:** Negative

**Number of Lymph Nodes Assessed:** 32

**Mismatch Repair (MMR) Status:** MMR-P (MSS)

**Lymphovascular Invasion:** Present

**Perforation:** Absent

**Obstruction:** Absent

**Other Information:** Lymph node status was negative, but extra nodal tumor deposits: N1c  
Patient received two does of 5-FU Oxaliplatin, but Oxaliplatin was stopped when the patient showed neuropathy and other signs of intolerable toxicity. The patient is continuing with capecitabine only.

### CASE SUBMITTED BY:

Frederick A. Slezak, MD, MBA

Summa Health System

Akron, OH

# Colon Case Study


## CLINICAL EXPERIENCE

Recurrence Score = **0**

### Prognosis for Stage III A/B Colon Cancer Patients Following Adjuvant Chemotherapy

The clinical validation study included patients from the NSAPB C-07 trial which randomized 409 stage III A/B patients to 5FU/LV versus 5FU/LV+oxaliplatin.<sup>1</sup>

The average 5 year risk of recurrence for patients who had a Recurrence Score<sup>®</sup> result of 0 was:



Other Considerations: The recurrence risk for patients with  $\geq 12$  nodes examined was lower than the risk for those with  $< 12$  nodes examined.

#### References:

1. Yothers et al. J Clin Oncol. 2013.